Skip to main content
Clinical Trials/ISRCTN54581790
ISRCTN54581790
Completed
Phase 4

Efficacy and safety of Cerebrolysin in the treatment of aphasia after acute ischemic stroke

The foundation for the study of neuroscience and neuroregeneration (SSNN)0 sites132 target enrollmentApril 29, 2020

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Patients with Broca or mixed non-fluent aphasia post ischemic stroke with onset 3-5 days prior to inclusion
Sponsor
The foundation for the study of neuroscience and neuroregeneration (SSNN)
Enrollment
132
Status
Completed
Last Updated
last year

Overview

Brief Summary

2024 Preprint results in https://doi.org/10.1101/2024.02.23.24303302 (added 19/08/2024)

Registry
who.int
Start Date
April 29, 2020
End Date
March 31, 2023
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
The foundation for the study of neuroscience and neuroregeneration (SSNN)

Eligibility Criteria

Inclusion Criteria

  • Current inclusion criteria as of 04/06/2020:
  • 1\. Radiologically (CT or MRI) and clinically confirmed diagnosis of acute ischemic stroke in the left MCA territory
  • 2\. Broca or mixed non\-fluent aphasia
  • 3\. Inclusion in the study between 3 and 5 days post\-stroke
  • 4\. Right\-handedness
  • 5\. Romanian as language of daily use
  • 6\. Signed informed consent
  • Previous inclusion criteria:
  • 1\. Radiologically (CT or MRI) and clinically confirmed diagnosis of acute ischemic stroke in the left MCA territory
  • 2\. Broca or mixed non\-fluent aphasia

Exclusion Criteria

  • 1\. Prior symptomatic ischemic or hemorrhagic stroke
  • 2\. Severe comprehension deficit that may compromise informed consent or understanding of instructions such as fluent aphasias (ex. Wernicke aphasia), or global aphasias
  • 3\. Contraindications to MRI
  • 4\. Preexisting neurodegenerative or psychiatric disease
  • 5\. Epilepsy or EEG\-documented epileptic discharges
  • 6\. Severe chronic renal or liver failure; (AST, ALT \> 4 times normal values, creatinine \> 4\)
  • 7\. Life\-threatening diseases
  • 8\. Auditory or visual deficits that cannot be corrected and might impair testing

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Evaluation of efficacy and safety of Cerebrolysin as add-on therapy in patients with acute stroke after failed recanalisation therapyAcute ischemic strokeCirculatory SystemStroke, not specified as haemorrhage or infarction
ISRCTN15233803niversity Hospital Centre Zagreb46
Completed
Phase 3
Can Cerebrolysin improve recovery after traumatic brain injury?Traumatic brain injury (TBI) with Glasgow Coma Scale (GCS) scores between 7 and 12.Nervous System Diseases
ISRCTN17097163EN: The foundation for the study of neuroscience and reuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)142
Completed
Phase 3
Cerebrolysin to prevent intracranial bleeding after intravenous thrombolysis (blood clot) in patients with ischemic strokeIschemic strokeCirculatory System
ISRCTN87656744State Autonomous Institution of Health Interregional Clinical Diagnostic Center341
Active, not recruiting
Phase 1
Is Cerebrolysin efficient in neurorecovery after moderate-severe traumatic brain injury?Moderate-severe traumatic brain injuryMedDRA version: 26.1Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2022-003382-38-ROFSNANO05012022440
Recruiting
Phase 3
Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.Stroke, IschemicStroke, AcuteStroke Sequelae
NCT04904341Military Institute od Medicine National Research Institute50